CASI Pharmaceuticals, headquartered in Beijing, focuses on developing, commercializing, and acquiring therapeutics, particularly in hematology oncology, with products like EVOMELA in the U.S. and multiple FDA-approved generics in China. The company, which employs 224 people, went public on August 23, 2021, and operates globally with a pipeline including CNCT19, BI-1206, and other drugs addressing unmet medical needs.
CASI filed a patent for "vcp/p97 inhibitor for the treatment of cancer" on Wed, November 9, 2022. The patent was officially published on Thu, June 8, 2023.
📡️ Health Care
Patents
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
